{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-25-283078","form_type":"8-K","ticker":"VRCA","cik":"0001660334","company_name":"Verrica Pharmaceuticals Inc.","filed_at":"2025-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.068225+00:00","generated_at":"2026-05-16T19:52:22.539568+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Verrica Q3 revenue $14.3M (YCANTH $3.6M, license $10.7M); net loss narrows to $0.3M","bullets":["Q3 net loss $0.3M ($0.03/sh) vs $22.9M loss ($4.88/sh) in Q3'24; non-GAAP net income $1.2M.","YCANTH dispensed units 14,093 in Q3 (+4.9% sequentially); nine-month total 37,642 (+120% YoY).","Received $10M milestone from Torii for Japan YCANTH approval; global Phase 3 for common warts started.","FDA aligned on Phase 3 design for VP-315 in basal cell carcinoma; positive EMA feedback supports MAA filing.","Cash $21.1M; sales force expanded to 45 reps, targeting 50 in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-25-283078","json":"https://secwatch.observer/filing/0001193125-25-283078.json","markdown":"https://secwatch.observer/filing/0001193125-25-283078.md","text":"https://secwatch.observer/filing/0001193125-25-283078.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1660334/000119312525283078/0001193125-25-283078-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1660334/000119312525283078/d99039d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T19:52:22.539568+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}